[{"orgOrder":0,"company":"Allecra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allecra Therapeutics Announces Positive Top-Line Results for Phase 3 ALLIUM Clinical Trial of EXBLIFEP","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"February 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Allecra Therapeutics"},{"orgOrder":0,"company":"MYR Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MYR Pharmaceuticals Receives Positive CHMP Opinion For HEPCLUDEX\u00ae (bulevirtide)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"GERMANY","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Peptide","graph2":"MYR Pharmaceuticals"},{"orgOrder":0,"company":"CureVac","sponsor":"University Medical Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CureVac and the University Medical Center Mainz Start Phase 3 Clinical Trial for COVID-19 Vaccine Candidate, CVnCoV, in Healthcare Workers","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"GERMANY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"CureVac"},{"orgOrder":0,"company":"Bayer AG","sponsor":"CureVac","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CureVac and Bayer join forces on COVID-19 vaccine candidate CVnCoV - joint press release","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"GERMANY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Bayer AG"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Cidara Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orphan Drug Designation Granted to Mundipharma's Rezafungin in EU for the Treatment of Invasive Candidiasis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"GERMANY","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Peptide","graph2":"Mundipharma"},{"orgOrder":0,"company":"CureVac","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CureVac Initiates Rolling Submission With European Medicines Agency for COVID-19 Vaccine Candidate, CVnCoV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"GERMANY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"CureVac"},{"orgOrder":0,"company":"CureVac","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CureVac Expands CVnCoV COVID-19 Vaccine Candidate Clinical Trial Analyses to Include Phase 2b\/3 Variant Specification and Efficacy Secondary Endpoint to Phase 2a","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"GERMANY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"CureVac"},{"orgOrder":0,"company":"CureVac","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CureVac\u2019s First-Generation COVID-19 Vaccine Candidate, CVnCoV, Continues Toward Phase 2b\/3 Efficacy Readout in Variant-rich Environment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"GERMANY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"CureVac"},{"orgOrder":0,"company":"InflaRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InflaRx Completes Enrollment of Vilobelimab Phase III Study in Severe COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"InflaRx"},{"orgOrder":0,"company":"Bayer AG","sponsor":"CureVac","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bayer, CureVac Terminate COVID-19 Shot Production Partnership","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"GERMANY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Bayer AG"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Cidara Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rezafungin Awarded Promising Innovation Medicine (PIM) Designation by the UK\u2019s Medicines and Healthcare Products Regulatory Agency (MHRA) for the Treatment of Invasive Candidiasis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"GERMANY","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Peptide","graph2":"Mundipharma"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Cidara Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mundipharma and Cidara Therapeutics Announce First Presentation of Results from Global Phase 3 ReSTORE Trial of Rezafungin for Treatment of Candidemia and\/or Invasive Candidiasis Demonstrating its Positive Efficacy and Safety Profile","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"GERMANY","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Peptide","graph2":"Mundipharma"},{"orgOrder":0,"company":"InflaRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InflaRx Announces Plans to Apply for Emergency Use Authorization from the US FDA for Vilobelimab for Treatment of Critically Ill COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"GERMANY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"InflaRx"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Medicines Agency Accepts Rezafungin Marketing Authorisation Application for the Treatment of Invasive Candidiasis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"GERMANY","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Peptide","graph2":"Mundipharma"},{"orgOrder":0,"company":"InflaRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InflaRx Announces Vilobelimab Phase III Results in Critically Ill COVID-19 Patients Published in The Lancet Respiratory Medicine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"InflaRx"},{"orgOrder":0,"company":"InflaRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InflaRx Submits Request for Emergency Use Authorization to US FDA for Vilobelimab for Treatment of Critically Ill COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"InflaRx"},{"orgOrder":0,"company":"Allecra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allecra Therapeutics Publishes Final Phase 3 ALLIUM Data in JAMA: Cefepime\/Enmetazobactam Met Criteria for Superiority","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"GERMANY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Allecra Therapeutics"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Napp Announces Acceptance of their Rezafungin Marketing Authorisation Application for the Treatment of Invasive Candidiasis to the UK Medicines and Healthcare Products Regulatory Agency","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"GERMANY","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Peptide","graph2":"Mundipharma"},{"orgOrder":0,"company":"InflaRx","sponsor":"Staidson Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"InflaRx Announces Amendment of Co-Development Agreement and Additional Equity Investment by Staidson in Connection with Regulatory Filing in China for Anti-C5a-Antibody for Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"GERMANY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"InflaRx"},{"orgOrder":0,"company":"Merck Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The European Medicines Agency (EMA) Validated Regulatory Application for Arpraziquantel, a Potential Treatment for Schistosomiasis in Preschool-Aged Children","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"GERMANY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Merck Group"},{"orgOrder":0,"company":"Merck Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Opens Enrollment in New Phase 3 Clinical Trials with Investigational Once-Daily Islatravir in Combination with Doravirine for Treatment of HIV-1 Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"GERMANY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Merck Group"},{"orgOrder":0,"company":"Allecra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allecra Therapeutics Submits New Drug Application to the U.S. FDA for EXBLIFEP for the Treatment of Complicated Urinary Tract Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"June 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Allecra Therapeutics"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
EXBLIFEP (cefepime/enmetazobactam) has been designed to combat anti-microbial resistance in gram-negative bacteria, especially resistance mediated by Extended Spectrum Beta Lactamases and which is investigated in patients with complicated urinary tract infections.
MK-8591A is a combination of islatravir and Doravirine which are being investigated as non-nucleoside reverse transcriptase translocation inhibitor of HIV-1.
Arpraziquantel completed phase 3 studies for schistosomiasis indication, as it cause severe spasms and paralysis of the worms' muscles. This paralysis is caused by a rapid Ca 2+ influx inside the schistosome.
Under the co-development agreement, BDB-001, an anti-C5a antibody that originated from the same cell line as vilobelimab, is being developed by STS for the treatment of severe COVID-19 and other inflammatory diseases in China.
CD101 (rezafungin) is a novel, once-weekly echinocandin being developed for both the treatment and prevention of serious fungal infections,demonstrated non-inferiority to the current standard of care in the treatment of candidemia and/or invasive candidiasis.
Among patients with cUTI caused by gram-negative pathogens, cefepime/enmetazobactam, compared with piperacillin/tazobactam, met criteria for noninferiority as well as superiority with respect to the primary outcome of clinical cure and microbiological eradication.
Vilobelimab (IFX-1) is a first-in-class monoclonal anti-human complement factor C5a antibody, which highly and effectively blocks the biological activity of C5a and demonstrates high selectivity towards its target in human blood.
The published data show that IFX-1 (vilobelimab) treatment improved survival with a relative reduction in 28-day all-cause mortality of 23.9% compared to placebo in the global data set.
European Medicines Agency filing is supported by the pivotal ReSTORE Phase III clinical trial results, where rezafungin (echinocandin/CD101) demonstrated non-inferiority to the current standard of care, caspofungin in the treatment of candidemia and/or invasive candidiasis.
IFX-1 (vilobelimab) is a first-in-class monoclonal anti-human complement factor C5a antibody, which highly and effectively blocks the biological activity of C5a and demonstrates high selectivity towards its target in human blood.